{"id":"doxil-and-vinorelbine","safety":{"commonSideEffects":[{"rate":"50%","effect":"Neutropenia"},{"rate":"30%","effect":"Anemia"},{"rate":"20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to cell cycle arrest at the G2/M phase and ultimately apoptosis. Vinorelbine, a vinca alkaloid, binds to tubulin and prevents microtubule polymerization, also inhibiting cell division.","oneSentence":"Docetaxel, a microtubule inhibitor, binds to tubulin and prevents microtubule assembly, thereby inhibiting cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:34:42.540Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Lung cancer"}]},"trialDetails":[{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT03618550","phase":"PHASE2","title":"Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-01","conditions":"Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma","enrollment":257},{"nctId":"NCT04388839","phase":"PHASE2","title":"Evolutionary Therapy for Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-29","conditions":"Rhabdomyosarcoma","enrollment":12},{"nctId":"NCT06377566","phase":"PHASE2","title":"A Study of BV-AVD in People With Bulky Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-04-17","conditions":"Hodgkin Lymphoma","enrollment":71},{"nctId":"NCT02489903","phase":"PHASE2","title":"RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2015-06","conditions":"Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors","enrollment":139},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06102824","phase":"PHASE2","title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-10-01","conditions":"HER2-negative Breast Cancer, Advanced Breast Cancer","enrollment":252},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06653972","phase":"PHASE2","title":"Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Wang Jiayu","startDate":"2024-11-01","conditions":"Her2-negative Metastatic Breast Cancer, Vinorelbine, Liposomal Doxorubicin","enrollment":30},{"nctId":"NCT03355157","phase":"PHASE4","title":"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2018-03-01","conditions":"Metastatic Breast Cancer","enrollment":130},{"nctId":"NCT06451302","phase":"NA","title":"Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yizhuo Zhang","startDate":"2024-04-17","conditions":"Ewing Sarcoma, Risk Stratification","enrollment":100},{"nctId":"NCT01619111","phase":"PHASE3","title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","status":"COMPLETED","sponsor":"Prof. Wolfgang Janni","startDate":"2012-02","conditions":"HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells","enrollment":105},{"nctId":"NCT04625907","phase":"PHASE1, PHASE2","title":"FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2020-09-17","conditions":"Rhabdomyosarcoma","enrollment":1672},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT04624984","phase":"PHASE2","title":"PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-04-01","conditions":"Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma","enrollment":42},{"nctId":"NCT01026220","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-12-07","conditions":"Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma","enrollment":166},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":"Hodgkin Disease Lymphoma","enrollment":60},{"nctId":"NCT00302003","phase":"PHASE3","title":"Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-02","conditions":"Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma","enrollment":287},{"nctId":"NCT00544765","phase":"PHASE3","title":"Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-09","conditions":"Breast Cancer","enrollment":2014},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT02733380","phase":"PHASE2","title":"Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2016-05","conditions":"Diffuse Large B-cell Lymphoma","enrollment":20},{"nctId":"NCT02628613","phase":"PHASE2","title":"Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations","status":"COMPLETED","sponsor":"Fudan University","startDate":"2015-12","conditions":"Breast Cancer","enrollment":91},{"nctId":"NCT01098266","phase":"PHASE3","title":"NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed","status":"COMPLETED","sponsor":"AGC Biologics S.p.A.","startDate":"2010-04-12","conditions":"Malignant Pleural Mesothelioma","enrollment":400},{"nctId":"NCT04021992","phase":"PHASE2","title":"GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-07-15","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":48},{"nctId":"NCT00011414","phase":"PHASE1","title":"Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-02-15","conditions":"Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma","enrollment":29},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT00148681","phase":"PHASE2","title":"Preoperative Herceptin and Navelbine for Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2001-05","conditions":"Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer","enrollment":49},{"nctId":"NCT03346642","phase":"PHASE1, PHASE2","title":"Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2017-05-01","conditions":"Primary Mediastinal Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT02331251","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2014-12","conditions":"Advanced Cancer, Breast Cancer, Sarcoma","enrollment":81},{"nctId":"NCT00194779","phase":"PHASE2","title":"Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-10","conditions":"Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer","enrollment":50},{"nctId":"NCT01698281","phase":"PHASE2","title":"Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"AEterna Zentaris","startDate":"2012-12","conditions":"Breast Cancer","enrollment":7},{"nctId":"NCT03359694","phase":"PHASE3","title":"Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-12","conditions":"Susceptibility, Genetic, Chemotherapy Effect","enrollment":300},{"nctId":"NCT01156753","phase":"PHASE2","title":"A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer","status":"COMPLETED","sponsor":"Celldex Therapeutics","startDate":"2010-07","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00176488","phase":"PHASE2","title":"Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2003-06","conditions":"Breast Cancer","enrollment":31},{"nctId":"NCT03006614","phase":"PHASE3","title":"PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shi Yanxia","startDate":"2016-04","conditions":"Breast Cancer Model, Effects of Chemotherapy, Breast Cancer","enrollment":320},{"nctId":"NCT00920153","phase":"PHASE3","title":"Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2008-05","conditions":"Lymphoma","enrollment":442},{"nctId":"NCT00006029","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-07","conditions":"Lymphoma","enrollment":91},{"nctId":"NCT00235235","phase":"","title":"A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer","status":"TERMINATED","sponsor":"Hoosier Cancer Research Network","startDate":"2005-09","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT00337194","phase":"PHASE2","title":"SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04","conditions":"Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT00225173","phase":"PHASE2","title":"Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease","status":"TERMINATED","sponsor":"Stanford University","startDate":"2001-10","conditions":"Hodgkin Disease","enrollment":45},{"nctId":"NCT01732939","phase":"","title":"Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer","status":"UNKNOWN","sponsor":"Hospital Affiliated to Military Medical Science, Beijing","startDate":"2012-05","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT00379457","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma","status":"UNKNOWN","sponsor":"European Paediatric Soft Tissue Sarcoma Study Group","startDate":"2006-06","conditions":"Sarcoma","enrollment":600},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10},{"nctId":"NCT01641406","phase":"PHASE2","title":"\"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer\"","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2011-03","conditions":"Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma","enrollment":60},{"nctId":"NCT00006372","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2000-02","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":10},{"nctId":"NCT00159094","phase":"PHASE2","title":"A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Hematology Oncology Consultants","startDate":"2003-10","conditions":"Metastatic Breast Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Doxil and Vinorelbine","genericName":"Doxil and Vinorelbine","companyName":"Hematology Oncology Consultants","companyId":"hematology-oncology-consultants","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel, a microtubule inhibitor, binds to tubulin and prevents microtubule assembly, thereby inhibiting cell division. Used for Breast cancer, Lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}